Alembic Pharmaceuticals has received
approval from the US Food & Drug Administration (USFDA) for its Abbreviated New
Drug Application (ANDA) Teriflunomide Tablets, 7 mg and 14 mg. The approved
ANDA is therapeutically equivalent to the reference listed drug (RLD), Aubagio
Tablets, 7 mg and 14 mg, of Sanofi-Aventis U.S., LLC (Sanofi-Aventis). Teriflunomide
tablets are indicated for the treatment of patients with relapsing forms of multiple
sclerosis.
Teriflunomide Tablets, 7 mg and 14 mg have an estimated market size of US$ 1.6 billion for twelve months ending December 2018 according to IQVIA. Alembic has settled the litigation and will launch the product as per the terms of the settlement.
Alembic now has a total of 91 ANDA approvals (79 final approvals and 12 tentative approvals) from USFDA.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
